UNSPSC 51393401: Ambuphylline or bufylline

This classification denotes a bronchodilator with the molecular formula C7H8N4O2.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VOU5V0B772, chemically known as 3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione, compound with 2-amino-2-methylpropan-1-ol (1:1) but generally known as ambuphylline, which bears US NIH Compound Identifier 21850. European Medicines Agency schedules Ambuphylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12843MIG.

World Health Organization schedules ambuphylline in its Anatomical Therapeutic Chemical (ATC) Classification. Ambuphylline or bufylline bears US NLM identifiers UMLS ID C0602745 and NCI Concept Code C76572. SMILES: CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC=N2.

UNSPSC 51393401 Ambuphylline or bufylline is a Commodity code that maps poorly to actual state and local procurement activity under recent solicitations. The code's nominal scope—a specific bronchodilator pharmaceutical—does not align with the recent opportunities tagged under it, which involve naloxone procurement and direct-to-manufacturer prescription program design rather than ambuphylline or bufylline products. State and local governments show minimal relevant recent activity under this code.

The two recent opportunities in the dataset target different pharmaceutical and pharmacy management objectives. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring vendors' experience with direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity involves ambuphylline or bufylline procurement. The mismatch between the code's pharmaceutical scope and the naloxone and prescription-management activities in recent solicitations suggests the code either sees very limited state and local demand or has been misapplied to these opportunities in the source system. Business development professionals evaluating this code should verify classification with issuing bodies and focus pursuit efforts on jurisdictions with documented respiratory-drug procurement needs rather than rely on the current activity signal.